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Abstract
Recently, we discovered a novel serum and cerebrospinal fluid (CSF) autoantibody (anti-Ca) to Purkinje cells in a
patient with autoimmune cerebellar ataxia (ACA) and identified the RhoGTPase-activating protein 26 (ARHGAP26;
alternative designations include GTPase regulator associated with focal adhesion kinase pp125, GRAF, and
oligophrenin-1-like protein, OPHN1L) as the target antigen. Here, we report on two new cases of ARHGAP26
autoantibody-positive ACA that were first diagnosed after publication of the index case study. While the index
patient developed ACA following an episode of respiratory infection with still no evidence for malignancy 52
months after onset, neurological symptoms heralded ovarian cancer in one of the patients described here. Our
finding of anti-Ca/anti-ARHGAP26 antibodies in two additional patients supports a role of autoimmunity against
ARHGAP26 in the pathogenesis of ACA. Moreover, the finding of ovarian cancer in one of our patients suggests
that anti-Ca/anti-ARHGAP26-positive ACA might be of paraneoplastic aetiology in some cases. In conclusion, testing
for anti-Ca/anti-ARHGAP26 should be included in the diagnostic work-up of patients with ACA, and an underlying
tumour should be considered in patients presenting with anti-Ca/ARHGAP26 antibody-positive ACA.
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Introduction
We recently described a novel serum and cerebrospinal
fluid (CSF) autoantibody in a patient with subacute auto-
immune cerebellar ataxia (ACA) [1]. In addition, we de-
monstrated that this antibody (termed anti-Ca), which
selectively binds to Purkinje cells when incubated with
primate or murine cerebellum tissue sections, targets the
RhoGTPase-activating protein 26 (ARHGAP26; alterna-
tive designations include GTPase regulator associated with
focal adhesion kinase pp125, GRAF, and oligophrenin-1-
like protein, OPHN1L).
Here we report on two new cases of ACA with anti-Ca/
anti-ARHGAP26 antibodies that were diagnosed since our
first publication on this novel serum reactivity. While the
index patient had developed ACA following an episode of
respiratory infection with still no evidence for cancer 52
months after onset, ACA heralded carcinoma in one of
the patients described here, suggesting that anti-Ca/anti-
ARHGAP26 is a potential marker of paraneoplastic ACA.
Case reports
Case 1
This previously healthy 68-year-old Caucasian woman
presented to her general practitioner with a three-month
history of dizziness. A cranial MRI was rated normal at
that time except for an empty sella. Laboratory analysis
disclosed asymptomatic hyperprolactinemia. The patient’s
medical history was otherwise unremarkable. No infec-
tions were reported to have preceded the onset of symp-
toms and the family history was negative for neurological
and oncological diseases. No specific treatment was
ordered at that time. Four months later, the patient was
admitted to hospital with signs of ataxia. Neurological
examination demonstrated a multidirectional gaze-evoked
nystagmus, cerebellar dysarthria, atactic gait, and severe
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difficulties in standing with feet together with eyes open;
tandem walking was impossible. Deep tendon reflexes and
plantar responses were normal. No signs of meningeal ir-
ritation were found. No apparent cognitive deficits were
noted. At that time, MRI of the head showed mild isolated
cerebellar atrophy. Visual and somotosensory-evoked po-
tentials were normal. Serum analysis revealed anti-neuronal
antibodies of then unknown specificity and low-titre
smooth muscle antibodies. Routine laboratory findings
were normal except for a slightly elevated erythrocyte sedi-
mentation rate (36 mm after 1 h) and increased lactate de-
hydrogenase (362 U/l; reference range, <250) blood levels.
No CSF analysis was performed at that time. A CT scan of
the abdomen and pelvis disclosed enlarged retroperitoneal
and mediastinal lymph nodes. Findings from mammog-
raphy and from X-ray and CT scanning of the thorax were
normal. Histology of the abdominal mass demonstrated a
nondifferentiated carcinoma likely of gynaecological ori-
gin. Laboratory analysis showed elevated serum levels of
cancer antigen (CA) 125 (2198 IU/ml; reference range,
<35), CA15-3 (54 IU/ml; reference range, <25), and
neuron-specific enolase (NSE; 39 ng/ml; reference range,
<16.3). Ovarian carcinoma was suspected and treatment
with carboplatin and docetaxel was commenced (seven
cycles over a period of six months). After the third cycle,
treatment with rituximab (four cycles) and intravenous
immunoglobulins (two cycles over five days each) was
added, which resulted in partial improvement of the
patient’s neurological symptoms. Eight months later,
follow-up examinations revealed a new retroperitoneal
mass (6 x 5 cm) and a nodule on the left ovarian vein; his-
tology suggested lymphatic infiltration due to a carcinoma
likely of gynaecological origin, and double adnexectomy
and hysterectomy were performed. At last admission, 24
months after onset, the patient reported increased gait
instability, nausea, and vomiting. Brain MRI revealed
atrophy of the cerebellar hemispheres and the cerebellar
vermis (Figure 1). Despite second-line chemotherapy with
carboplatin and cyclophosphamide, her neurological symp-
toms are still advancing slowly.
Case 2
A 38-year-old Iranian man presented with a nine-month
history of cerebellar ataxia and dysarthria, weight loss,
and vomiting. Brain MRI showed cerebellar atrophy. CSF
analysis showed CSF-restricted oligoclonal bands and 5
cells/μl. No further clinical data were available from this
patient retrospectively.
Immunological studies
Methods
Immunohistochemistry (IHC)
IHC was performed on cryosections of adult rhesus monkey,
rat, and mouse cerebellum tissue (Euroimmun, Luebeck,
Germany) as previously described [1]. Briefly, sections were
pretreated with formalin and 1% 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS) in PBS,
blocked with 10% goat serum and then incubated with pa-
tient serum for 1 h. Binding of human immunoglobulin
(Ig)G, IgA, and IgM to CNS tissue was detected by using
polyclonal goat anti-human IgG antibodies conjugated to
fluorescein isothiocyanate (FITC) (Euroimmun) or Alexa
Fluor™ (AF) 568 (Invitrogen, Karlsruhe, Germany), and
polyclonal goat anti-human IgM and anti-human IgA
antibodies conjugated to FITC (Euroimmun), respectively.
Sections were then mounted using glycerol standard im-
munofluorescence mounting medium containing 4',6-
diamidino-2-phenylindole (DAPI) (1:1000) (Euroimmun)
or ProLong Gold antifade reagent (Invitrogen). Slides
were analyzed on a Nikon 90i upright fluorescence mi-
croscope and a Nikon A1 confocal microscope (Nikon
Figure 1 Magnetic resonance imaging of the brain, patient 1. Sagittal (A, T1 weighted) and coronal (B, FLAIR T2 weighted) MRI showing
cortical atrophy in the cerebellar hemispheres and the inferior vermis with enlargement of the cerebellar sulci, the fourth ventricle and the
inferior cerebellar cistern, but no atrophy of the cerebral cortex, midbrain, or pons.
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Imaging Center, University of Heidelberg, Heidelberg,
Germany).
Immunoglobulin G (IgG) subclass analysis
To evaluate IgG subclasses, serum and CSF samples were
tested by IHC on mouse cerebellum sections as described
above, with the following modifications: sections were
blocked with 10% donkey serum; nonconjugated sheep
anti-human IgG antibodies specific for IgG subclasses 1 to
4 (Binding site, Germany) were substituted for the FITC-
labeled goat anti-human IgG antibody; and AF568-labeled
donkey anti-sheep IgG (Invitrogen; absorbed against
human IgG) was used to detect the subclass-specific
antibodies.
Preadsorption experiments
To confirm ARHGAP26 specificity, sera were pread-
sorbed overnight with human full-length ARHGAP26
(Biozol, Eching, Germany) and supernatants were tested
by IHC as described above.
Dot blot assay
Protran BA79 nitrocellulose membranes (0.1 μm)
(Whatman, Fisher Scientific, Schwerte, Germany) were
spotted with a 0.14 μg/μl solution of human full-length
ARHGAP26 (10 μl/spot; Biozol). After drying, mem-
branes were blocked with 5% bovine serum albumin
(BSA) in Tris-buffered saline (TBS) for 1 h at room
temperature (RT), washed three times in TBS with
0.05% Tween (TBS-T), and then incubated with a 1:20
dilution of the patient's serum in 0.1% BSA/TBS-T for 1
h at RT. A donkey anti-human IgG antibody labeled
with IRdye 700DX (Rockland, Gilbertsville, PA, USA)
was used to detect bound IgG. Stripes were finally
washed in TBS and analyzed using an Odyssey™ fluores-
cence scanner (Licor, Lincoln, NE, USA) and Odyssey™
2.0.40 application software (Licor).
Figure 2 Indirect immunofluorescence (IIF) on mouse
cerebellum tissue sections revealed the typical anti-Ca staining
pattern as previously described [1]. GL, granular layer; PC, Purkinje
cell layer; ML, molecular layer. Interneurons are spared (arrowheads).
Figure 3 Anti-Ca antibodies belonged mainly to the IgG1 and IgG2 subclasses (left and middle panels). Patient 1 was, in addition,
positive for anti-Ca antibodies of the IgM class (right panel) and patient 2 for anti-Ca antibodies of the IgA class (not shown).
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Testing for coexisting antibodies
All samples were tested for anti-Hu, -Yo, -Ri, -CV2/
CMRP5, -Ma/Ta, -Tr, -amphiphysin, -aquaporin-4, -GAD,
-MAG, and -myelin antibodies by IHC on mouse, rat,
and monkey brain and peripheral nerve tissue sections
(Euroimmun, Luebeck, Germany), for anti-Hu, -Yo, -Ri,
-CV2/CMRP5, -Ma/Ta, and -amphiphysin antibodies by
using a commercially available line blot assay (Euroim-
mun, Germany), and for anti-NMDA-type glutamate re-
ceptor, anti-AMPA-type glutamate receptor, anti-GABA-B
receptor, anti-CASPR2, anti-LGI1, anti-AQP4, and anti-
glycine receptor antibodies using a panel of recombinant
cell-based assays (Euroimmun, Germany).
Results
HC on formalin-fixed cerebellum tissue sections revealed
selective binding of IgG to somata, axons, dendritic
trunks, and dendritic branches of Purkinje cells (PCs) in a
pattern identical to that recently described in a patient
with ARHGAP26 antibodies (anti-Ca) and ACA (Figure 2)
at a titre of 1:32,000 in patient 1 and 1:3,200 in patient 2.
As in the index patient, anti-Ca antibodies belonged
mainly to the IgG1 subclass (patient 1: IgG1>=IgG2>>Ig-
G4>>IgG3; patient 2: IgG1>>IgG2>IgG3). In addition,
patient 1 was positive for anti-Ca antibodies of the IgM
class (Figure 3) and patient 2 for anti-Ca antibodies of the
IgA class. Both patients tested positive in a dot blot assay
using recombinant human full-length ARHGAP26 as anti-
gen as previously described (Figure 4). Preadsorption of
the patient’s serum with recombinant human full-length
ARHGAP26, but not preadsorption with a control protein,
resulted in complete disappearance of the cerebellar stain-
ing pattern as detected by IHC, again confirming the anti-
bodies’ specificity to ARHGAP26 (Figure 5). Using IHC
on brain tissue sections, a commercial line blot assay, and
a panel of antigen-specific cell-based assays to detect clas-
sical paraneoplastic antibodies, no evidence was found for
anti-Hu, anti-Ri, anti-Yo, anti-Ma, anti-Ta, anti-Tr, PCA-2,
ANNA-3, anti-CV2/CRMP5, anti-amphiphysin, ANNA3,
PCA2, anti-GAD, anti-NMDA receptor, anti-AMPA re-
ceptor, anti-GABA-B receptor, anti-CASPR2, anti-LGI1,
anti-glycine receptor, anti-myelin, or anti-MAG anti-
bodies. All diagnostic tests reported here were performed
as part of the patients' routine clinical workup.
Discussion
Recently, we reported on a newly discovered serum and
CSF autoantibody in a patient with ACA [1]. This new
Figure 4 Binding of serum IgG to human recombinant full-
length ARHGAP26 as demonstrated in a dot blot assay. OND,
other neurological diseases.
Figure 5 Preadsorption of the patients’ sera with recombinant human full-length ARHGAP26 but not preadsorption with a control protein
resulted in complete disappearance of the typical anti-Ca cerebellar staining pattern as detected by IIF (left panel: binding of serum IgG
from patient 1 to a cerebellum tissue section before preadsorption with ARHGAP26, right panel: after preadsorption with ARHGAP26).
Jarius et al. Journal of Neuroinflammation 2013, 10:7 Page 4 of 6
http://www.jneuroinflammation.com/content/10/1/7
antibody bound selectively to Purkinje cell somata, den-
drites, and axons on primate and murine cerebellum tis-
sue sections, and was shown to target ARHGAP26. Here,
we report on two newly diagnosed cases of anti-Ca/anti-
ARHGAP26-positive ACA.
Occurrence of ARHGAP26 antibody-positive ACA led
to the diagnosis of ovarian carcinoma in one of the
patients reported here, suggesting a possible paraneoplas-
tic aetiology of the condition. Paraneoplastic neurological
disorders count among the most common causes of
antibody-associated ACA [2,3]. It is of note in this context
that ARHGAP26 has been shown to be expressed in a
subset of ovarian cancer tissues, partly at high levels, while
it is absent or present only at low levels in normal ovarian
tissue [4]; however, no tumour tissue from patient 1 was
available for analysis in this study.
Antibodies previously demonstrated in patients with
paraneoplastic ACA included anti-Hu [5], anti-Yo [6],
anti-CV2/CRMP5 [7,8], anti-Tr [9,10], anti-Zic4 [11],
anti-protein kinase C gamma (PKCγ) [12], anti-mGluR1
[13,14], anti-PCA2 [15], anti-ANNA3 [16], or voltage-
gated calcium channels (VGCC) [17]. None of these anti-
bodies was detected in the patient reported here.
Histologically, a diagnosis of undifferentiated carcinoma
was made. However, as a caveat, elevated serum levels of
neuron-specific enolase (NSE), a marker of neuroendo-
crine tumours, were detected. This is of potential interest
since tumours of neuroendocrine differentiation such as
small-cell lung cancer and neuroblastoma have previously
been implicated in a wide range of paraneoplastic neuro-
logical disorders, including ACA [2,18]. As no secondary
carcinoma of neuroendocrine differentiation has been
found in repeated follow-up examinations, we cannot ex-
clude that the primary tumour contained neuroendocrine
components that went unrecognized. Notably, ARHGAP26
has been found to be upregulated in neuroendocrine
tumours [19]. Alternatively, the elevated NSE serum levels
might be of neuronal origin, reflecting the marked neu-
ronal loss as detected on MRI.
In the second case reported here, the tumour status is
unknown as the patient is lost to follow-up; however, the
development of ACA was reportedly associated with un-
usual weight loss in this patient.
Now that it is clear that anti-ARHGAP26/GRAF is
present in more patients with ACA, studies on the immu-
nopathological impact of this new serum reactivity are
warranted. So far, it is unknown whether the antibody it-
self causes neurological damage (as has been shown for
some of the novel anti-CNS autoantibodies described over
the past of couple of years [20]) or whether the antibody
is merely a disease marker of ACA while the actual dam-
age is T cell-mediated (as it is thought to be the case with
the classical onco-neuronal antibodies). Of note, as in the
index case, anti-Ca/anti-ARHGAP26 belonged to the
complement-activating IgG1 subclass in the two new
cases reported here, confirming that these new antibodies
may possibly act on PCs via complement-dependent
mechanisms. In this context, it is of note that patient 1
was, in addition to IgG, positive for IgM antibodies to
ARHGAP26. IgM antibodies are generally known to be
more potent activators of complement than IgG. Auto-
antibodies of the IgM class have been reported also in
other autoimmune diseases of the CNS [21]. By contrast,
patient 2 as well as well as the index patient [1] were nega-
tive for ARHGAP26-IgM.
Our finding of high-titre anti-Ca/anti-ARHGAP26
antibodies in two additional patients with ACA strongly
supports a role for autoimmunity against ARHGAP26 in
the pathogenesis of this rare condition and proves that
the index patient was not a singular case. Moreover, the
finding of ovarian cancer in one of our patients suggests
that anti-Ca/anti-ARHGAP26-positive ACA might be of
paraneoplastic aetiology in some cases. In conclusion, test-
ing for anti-Ca/anti-ARHGAP26 should be included in the
diagnostic work-up of patients with ACA; while more
cases have to be evaluated before a strict recommendation
can be made as to whether broad tumour screening is
generally required in patients with anti-Ca/ARHGAP26
antibody-positive ACA, non-harmful screening procedures
such as ultrasound examination for ovarian cancer and,
possibly, tumour marker testing seem warranted.
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